TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Reduction of Concussion Symptoms Through the Use of Osteopathic Manipulative Therapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients referred to the Geisinger sports medicine clinic or athletic training room for concussion evaluation and management~2. Age less than 25 years old~3. Enrolled in high school or college~4. Participating in a sport at either collegiate or high school level~Exclusion Criteria:~1. Diagnosis does not meet criteria for concussion~2. Symptoms of concussion not present on initial visit~3. Patient unable to tolerate the OMT treatment~4. Patient needs intervention beyond standard concussion management~5. Patients not able to provide consent to be a part of the study

- Gender: ALL
- Minimum Age: None
- Maximum Age: 24 Years
- Healthy Volunteers: f

Study Arms:
- Osteopathic Manipulative Therapy (OMT) Treatment Group (Type: EXPERIMENTAL): Initial concussion treatment will involve OMT in addition to standard of care treatment. The OMT practitioner, using a strong anatomic knowledge base, applies specific genital forces in the dysfunctional area, thus providing aid to the body's innate mechanisms of healing. During OMT, a patient's muscles and joints are moved using techniques that include stretching, gentle pressure, and resistance.
- Standard of care concussion treatment group (Type: ACTIVE_COMPARATOR): Standard of care concussion treatment without OMT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must be female, at least 18 years of age, but not older than 90 years, with advanced or metastatic HER2+ breast cancer and a life expectancy of more than 6 months~* Patient must have confirmed HER2 overexpression or gene-amplified tumor via immunohistochemistry \[IHC\] with IHC 3+ or IHC 2+ with confirmatory fluorescence in situ hybridization \[FISH\]+ or \[ISH\]+~* Patients must have had at least 1 line of anti-HER2 directed therapy either in the metastatic or early-stage disease setting~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~Exclusion Criteria:~* Patient has had previous treatment with poziotinib.~* Patient has received anticancer chemotherapy, TKIs, biologics, immunotherapy, radiotherapy, or investigational treatment within 15 days. (There is no washout for hormonal therapy for breast cancer).~* Patient has a life expectancy less than 3 years due to other malignancies.~* Patient is pregnant or breast-feeding.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Poziotinib (Type: EXPERIMENTAL): * Part 1: Dose Finding The MTD/MAD of poziotinib in combination with the standard dose of T-DM1 will be determined by using a 3+3 design. At least 3 patients may be enrolled in each cohort before a decision is made to proceed to the next cohort.~* Part 2: MTD/MAD Expansion An additional 10 patients will be treated at the dose identified during Part 1 to further evaluate the combination at the MTD or the MAD.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Exelon Transdermal Patch in Amnestic Mild Cognitive Impairment Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of amnestic MCI~* In good general health with no diseases expected to interfere with the study~* Ability to undergo MRI~* Fluent in English~* Stable prescription dosages 1 month prior to testing~* Carrier of the APOE e4 allele (determined by blood draw at screening visit)~Exclusion Criteria:~* Neurological illness/conditions~* Medical illnesses/conditions that may affect brain function~* Prior history of use of any cholinesterase inhibitor~* Instable or severe cardiovascular disease or asthmatic condition

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Exelon transdermal patch (Type: ACTIVE_COMPARATOR): Exelon \[rivastigmine\] transdermal patch
- Placebo transdermal patch (Type: PLACEBO_COMPARATOR): Placebo transdermal patch

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age and above.~* Definite diagnosis of acute thrombotic thrombocytopenic purpura (TTP).~* Thrombocytopenia.~* Diagnostic signs of microangiopathic hemolytic anemia.~Exclusion Criteria:~* Congenital thrombotic microangiopathies.~* Alternative secondary cause for microangiopathy.~* Co-morbid illness limiting life expectancy to less than 3 months independent of TTP.~* Patients known to be HIV positive.~* Patients known to have lupus.~* Refusal to accept blood products.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Uniplas (Type: EXPERIMENTAL): Participants will receive Uniplas intravenously in 4 cycles of 7 to 9 days each for 1 month. The first cycle will consist of 1.5 plasma volume exchanges (= 75 mL/kg) for 3 consecutive days, followed by a minimum of 4 and a maximum of 6 daily single volume plasma exchanges (= 50 mL/kg). Subsequent treatment will depend upon the response of the participant to the first cycle, as assessed by a blinded assessor.
- Cryosupernatant plasma (Type: ACTIVE_COMPARATOR): Participants will receive cryosupernatant plasma intravenously in 4 cycles of 7 to 9 days each for 1 month. The first cycle will consist of 1.5 plasma volume exchanges (= 75 mL/kg) for 3 consecutive days, followed by a minimum of 4 and a maximum of 6 daily single volume plasma exchanges (= 50 mL/kg). Subsequent treatment will depend upon the response of the participant to the first cycle, as assessed by a blinded assessor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Second Line Treatment of Knee Osteochondral Lesion With Treated Osteochondral Graft

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female patients between the ages of 18 and 55~  * osteochondral lesions of the knee due to trauma or osteochondritis dissecans or removal treatment ( lesion post autograft)~ * Osteochondral lesion \> grade II- ICRS~ * One lesion or 2 concomitant lesions (tibial plateau, patella and condyles )at least one lesion has been pretreated by mosaicplasy or ACI. These treatment would have to have been made at least 18 months before inclusion~ * Presence of disabling and clinically meaningful symptoms (subjective IKDC \< 65, no improvement for 3 months)~ * No significant obesity (BMI \< 30)~ * Accompanying ligamentous and meniscal lesions, joint malalignment and patella femoral instability are authorized and corrected concurrently.~ * Patient able to understand, sign and date the informed consent form~ * Patient affiliated with a national health insurance system or who is the beneficiary of such as system~ * Women of childbearing age may not be included in the clinical trial unless their pregnancy test is negative. If this test is negative, they will be asked to use an effective birth control method during the entire the study.~Exclusion Criteria:~* - Pregnant or breast feeding women: Women of childbearing age will be asked to undergo a pregnancy test before being enrolled into the study and to use an effective birth control method.~* Presence of osteoarthritis, rheumatoid arthritis, any other condition of knee joint that, in the surgeon's opinion, is likely to compromise the allograft's outcome~* Excessive laxity or recurrent instability that could affect the score evaluation without concomitant ligamentoplasty~* Presence of an ulcerative disease, heavy smoking, tuberculosis, chronic psychiatric disorder or disease requiring long-term treatment with a medication that would affect bone or joint metabolism~* Persons with cancer or a history of cancer~* Persons deprived of their freedom by a judicial or administrative decision~* Adults subject to legal protection measures or who are unable to provide their consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- OD-PHOENIX (Type: EXPERIMENTAL): treatment of 1 to 5 osteochondral allograft cylinders in mosaic

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the DAISe System During Neurointervention for Acute Ischemic Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 85 years.~* Diagnosis of acute ischemic stroke with study enrollment time \< 8 hours from onset of symptoms.~* Disabling stroke defined as a baseline NIHSS \> 6.~* Pre-stroke (24 hours prior to stroke onset) independent functional status in activities of daily living with modified Rankin Score 0-1.~* If thrombolytic therapy (tPA) is administered, it must be administered per the prescribing information.~* Confirmed symptomatic intracranial occlusion, based on single phase, multiphase or dynamic CTA, at one or more of the following locations: Carotid T/L, M1 MCA, or M1-MCA equivalent (2 or more M2-MCAs), or M2-MCA.~* The following baseline imaging criteria should be met: MRI criterion: ASPECTS Score \> 4 OR CT criterion: ASPECTS \> 6~* Signed informed consent from patient or legally authorized representative.~Exclusion Criteria:~* CT or MRI evidence of recent/ fresh hemorrhage on presentation.~* Clinical history, past imaging or clinical judgment suggests that the intracranial occlusion is chronic.~* Rapidly improving neurological deficits based on the investigator's clinical judgement.~* Pregnancy~* Severe contrast allergy or absolute contraindication to iodinated contrast.~* No femoral pulses or very difficult endovascular access that will result in an inability to deliver endovascular therapy.~* Evidence of dissection in the carotid or middle cerebral arteries.~* Severe unilateral or bilateral carotid artery stenosis requiring treatment at the time of the procedure as determined during diagnostic angiography.~* Renal failure (serum creatinine level ≥ 4 mg/dL or on dialysis).~* Severe, sustained hypertension (SBP \>185 mmHg or DBP \>110 mmHg).~* Cerebral vasculitis.~* Suspicion of aortic dissection, presumed septic embolus or suspicion of bacterial endocarditis.~* Clinical symptoms suggestive of bilateral stroke or occlusions in multiple vascular territories (e.g., bilateral anterior circulation, or anterior/posterior circulation).~* Seizure due to stroke.~* Platelet count \< 50,000/mm3.~* A severe or fatal comorbid illness that will prevent improvement or follow-up or that will render the procedure unlikely to benefit the patient.~* Patient is unable or unwilling complete follow up visits.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- DAISe System (Type: EXPERIMENTAL): The DAISe System consists of the DAISe thrombectomy device used in with the Q Aspiration Catheter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Molecular Determinants of Coronaruy Artery Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: FAMILY_BASED
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males at least 45 years old and premenopausal females at least 50 years old at the time of onset of any of the following:~* PTCA~* MI~* CABG~* Must have a living sibling meeting the same criteria.~Exclusion Criteria:~* Substance Abuse in the absence of angiographic coronary stenosis~* Congenital Heart Disease

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Cases (Type: None): premature CAD and MI, AVM
- Controls (Type: None): No CAD, MI, AVM

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: PsA Treatment With hOKT3γ1 (Ala-Ala)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of psoriatic arthritis. Participants do not need to have concurrent psoriasis to participate in the study;~* Active inflammation in 3 or more joints;~* Currently receiving ongoing therapy with methotrexate or azathioprine; and~* Willing to use acceptable forms of contraception.~Exclusion Criteria:~* Active infection with HIV, hepatitis C virus, or hepatitis B virus;~* Uncompensated heart failure or a recent myocardial infarction (heart attack) within the 6 months prior to study entry;~* Certain other serious illnesses or cancers;~* Participation in another clinical trial within the 6 weeks prior to study entry; or~* Pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- hOKT3gamma1 (Ala-Ala) (Type: EXPERIMENTAL): Escalating dose of hOKT3gamma1 (Ala-Ala) given intravenously over 5 days of each 28 day cycle
- Placebo (Type: PLACEBO_COMPARATOR): Intravenous dose of placebo given over 5 days of each 28 day cycle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Effectiveness and Safety of Gabapentin for Post-operative Pain After Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women undergoing elective cesarean delivery~Exclusion Criteria:~* Patients unable to communicate in English~* Patients with an American Society of Anesthesiologists (ASA) classification of 3 or higher~* Patients with contraindications to any of the medications used in the study~* Patients with contraindications to spinal anesthesia~* Patients who have taken any pain medication in the past week~* Patients with fetuses having congenital abnormalities~* Patients with severe mental disorders~* Patients with HIV or hepatitis infections~* Intravenous drug users~* Patients with uncontrolled hypertension and diabetes~* Patients with central nervous system tumours

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Gabapentin
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Real Life Assessment of Abilify Maintena

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* The patient must be 18 (19 for patients from British Columbia) years of age or older.~* The patient must have been diagnosed with schizophrenia.~* The patient must be at least mildly ill (CGI-S score of ≥3).~* The treating physician must have reached the decision to treat the patient with Abilify Maintena™ prior to and independently of soliciting the patient to participate in the study.~* The patient and legal guardian (if applicable and when allowable by law) must have signed an informed consent indicating the understanding of the study and allowing the use of their anonymous data for the purposes of the study.~* The patient and caregiver(s) (if applicable) must be fluent in English or French, in order to be able to complete the questionnaires.~Exclusion Criteria~* The patient does not comprehend or refuses to sign the informed consent.~* The patient has any contraindications to the use of Abilify Maintena™ as specified in the Canadian Product Monograph.~* The patient has previously received one or more doses of Abilify Maintena™.~* The patient presents a significant suicidal risk as judged by the investigator.~* The patient is a pregnant or lactating female.~* The patient is a member of the study personnel or of their immediate families, or is a subordinate (or immediate family member of a subordinate) to any of the study personnel.~* The patient has previously been enrolled in this study.~* The patient is, in the investigator's opinion, unlikely to comply with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of the Efficacy of Topical Ibuprofen to Oral Ibuprofen in Adolescent Athletes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 12-19yo~* soft tissue injury or flare up of soft tissue injury within 10 days to 8 weeks~Exclusion Criteria:~* Known hypersensitivity to aspirin or any NSAID,~* allergy to eggs or egg products~* history of asthma, renal disease, GI disease, active or suspected bleeding peptic ulcer (past or present), anemia, hypertension, other systemic disease significantly affecting liver or renal function~* serious injury within six months~* currently on anticoagulants~* pregnant or lactating females~* active arthritis in affected limb~* open wounds, infected skin or fractures~* opioid use within 7 days~* severe psychological disorder~* prior topical medication applied to the painful region/area of study

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Active ibuprofen liposomal transdermal gel with placebo ibuprofen capsule
- 2 (Type: OTHER): Placebo ibuprofen liposomal transdermal gel with active ibuprofen capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Vivax in Pregnancy in Brazil (PAACT-PV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age \>16 weeks (determined by LMP and fundal height)- if there is discordance between the two, the more conservative estimate (i.e. lower) will be used, to prevent accidental exposure of a 1st trimester fetus~* Normal fetal heart beat detected by Doppler~* Presence of asexual P. vivax parasitemia ≤ 50,000 parasites/microliter (thick smear)~* Willing to sign or thumb print informed consent~* Willing to return for scheduled follow up visits for treatment and observation until delivery~* Willing to deliver in health facility~Exclusion Criteria:~* Pregnancy \< 16 weeks~* Microscopically confirmed P. falciparum or mixed infection/ parasitemia (P. vivax and another species of Plasmodium, i.e. P. vivax, P. ovale, or P. malariae)~* History of allergy or hypersensitivity to interventional drugs~* Exposure to antimalarial drugs and other drugs with antimalarial activity within the past 2 months, as determined by history from the woman (quinine, mefloquine, or artemisinin derivatives, including AL and MA)~* Patients taking drugs with possible interaction with study drugs (ie. warfarin, digoxin)~* History or family history of epilepsy or psychiatric disorder~* Presence of signs and symptoms of severe malaria, severe illness, or danger signs~* Hemoglobin \< 7 g/dl~* Inability to tolerate oral medication (repeated vomiting, impairment of consciousness).~* History of chronic disease including diabetes, renal failure, hepatic failure, heart disease requiring anti-arrhythmic drugs or warfarin, HIV/ AIDS, known hemoglobinopathy~* Participant's inability to return for follow up visits~* Age \<15 years

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mefloquine- Artesunate (Type: EXPERIMENTAL): Mefloquine- Artesunate (Farmaguinhos, Brazil): tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
- Artemether-Lumefantrine (Type: EXPERIMENTAL): Artemether-Lumefantrine, Lumet, Cipla 4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
- Chloroquine (Type: ACTIVE_COMPARATOR): Chloroquine (Farmaguinhos, Brazil): Tablets containing 250 mg Chloroquine salt given as 4 tablets at once on the first day (or 10 mg/kg) followed by 3 tablets once daily for the next 2 days (or 7,5 mg/kg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues